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ABSTRACT
Introduction There is a growing concern about the 
misuse of over the counter (OTC) and prescription only 
medication (POM) because of the impact on physical and 
mental health, drug interactions, overdoses and drug- 
related deaths. These medicines include opioid analgesics, 
anxiolytics such as pregabalin and diazepam and 
antidepressants. This protocol outlines how a systematic 
review will be undertaken (during June 2021), which 
aims to examine the literature on the pattern of OTC and 
POM misuse among adults who are accessing substance 
misuse treatment services. It will include the types of 
medication being taken, prevalence and demographic 
characteristics of people who access treatment services.
Methods and analysis An electronic search will be 
conducted on the Cochrane, OVID Medline, Pubmed, 
Scopus and Web of Science databases as well as grey 
literature. Two independent reviewers will conduct the 
initial title and abstract screenings, using predetermined 
criteria for inclusion and exclusion. If selected for inclusion, 
full- text data extraction will be conducted using a pilot- 
tested data extraction form. A third reviewer will resolve 
disagreements if consensus cannot be reached. Quality 
and risk of bias assessment will be conducted for all 
included studies. A qualitative synthesis and summary of 
the data will be provided. If possible, a meta- analysis with 
heterogeneity calculation will be conducted; otherwise, 
Synthesis Without Meta- analysis will be undertaken for 
quantitative data. The reporting of this protocol follows 
the Preferred Reporting Items for Systematic Reviews and 
Meta- Analyses.
Ethics and dissemination Ethical approval is not 
required. Findings will be peer reviewed, published and 
shared verbally, electronically and in print, with interested 
clinicians and policymakers.
PROSPERO registration number CRD42020135216.
INTRODUCTION
The inappropriate use (misuse) of over the 
counter (OTC) and prescription only medi-
cation (POM), where products are taken 
(and often the administration route or dose 
is altered), for nonmedical purposes, is a 
growing concern internationally.1 2 Although 
such use of OTC and POMs does not always 
result in dependency, they may be used 
in isolation or in combination, including 
alongside illicit substances and/or alcohol. 
Concomitant use of medicines, which have 
additive sedating and respiratory depressant 
effects, are of particular concern, especially 
opioids (such as fentanyl and oxycodone), 
benzodiazepines and gabapentinoids due 
to the risk of accidental overdose and drug- 
related deaths.3–6
OTC and POM misuse has also been associ-
ated with notable drug interactions, physical 
and mental health effects, such as psychosis, 
blood- borne virus transmission, renal failure 
and QT prolongation (that may result in 
tachycardias such as torsades de pointes), 
which may be life threatening.7–9 Drug misuse 
can be associated with significant socioeco-
nomic impact for the person, their friends, 
family and the wider community. It may lead 
to incidents that may be significant, such as 
falls, road traffic collisions and acts of aggres-
sion or violence against self or others.10
Medication may also be taken to potentiate 
psychoactive effects or manage side- effects 
of recreational drug use, such as erectile 
dysfunction medication for sexual perfor-
mance associated with methamphetamine.11 
Strengths and limitations of this study
 ► This protocol outlines how a systematic review will 
be undertaken to provide a comprehensive overview 
of the patterns of over the counter and prescription 
only medication misuse by adults who are accessing 
substance misuse treatment services.
 ► Two reviewers will independently undertake study 
selection, data extraction and assessment of risk 
bias, and a third reviewer will resolve disagreements 
and review findings.
 ► The results will include the types of medication 
being taken, prevalence and associated character-
istics, so that the needs of people who access treat-
ment services may be better understood.
 ► A lack of high- quality studies may be a potential 
limitation.
 ► Where available, internationally validated tools will 
be used for data syntheses and assessing bias risk 
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Motivations for OTC and POM misuse may not be solely 
for recreational or euphoric effect: some people may 
be self- medicating for withdrawal symptoms, under-
lying anxiety disorders or pain, as could be the case with 
baclofen, beta- blockers and opioids, respectively.12–14 
OTC and POMs may be used to change appearance such 
as topical steroids to change skin pigmentation15 and 
diuretics, laxatives and stimulants for weight manage-
ment.16 Medicines may also be taken to improve perfor-
mance, such as cognitive enhancers in academia.17
Sometimes the psychoactive effect of OTC and POMs 
may only become apparent when taken via an alternative 
route, such as Buscopan (hyoscine N- butyl bromide), 
which when smoked produces hallucinations, and the 
antitussive dextromethorphan and loperamide (for 
diarrhoea) when used at significantly high doses, can 
have euphoric effects.18–20 When being misused, formu-
lations such as buprenorphine tablets may be crushed 
and administered by injection,21 and fentanyl may be 
extracted from transdermal patches and administered 
by all routes of administration.22 Other examples include 
codeine, which can be combined with other substances to 
create new concoctions such as lean23 or extracted from 
combination products using techniques such as ‘cold- 
water extraction’.24
In 2016, a report from the UK governments’ Advisory 
Council on the Misuse of Drugs suggested that the misuse 
of prescription- only painkillers, benzodiazepines, z- drugs 
and increasingly gabapentinoids is prevalent, with the 
need for increased vigilance surrounding other medicines 
including quetiapine, baclofen and stimulants; the need 
to consider OTC codeine as a ‘precursor to the misuse of 
prescription opioids’ was also highlighted.25 Misuse may 
be detected and explored in a variety of ways, using qual-
itative methodologies such as surveys, interviews, focus 
groups and netnographic techniques.26–32 Qualitative and 
quantitative information can be obtained from clinical 
records, surveys, prescribing data, postmarketing surveil-
lance, pharmacovigilance studies and electronic medica-
tion dispensing systems.33–36 Quantitative data may also 
be obtained from drug tests,37 38 and as with any method-
ology, this has limitations; for example, OTC and POMs 
may not be detectable or may give false- positive results 
on drug tests that are routinely used in substance misuse 
services (SMS).20 39
While the misuse of OTC and POMs is thought to be 
increasing, actual prevalence remains unknown due to a 
lack of appropriate monitoring systems.25 Public Health 
England (PHE) published the results of their landmark 
review into dependency and withdrawal associated with 
some POMs in 2019, which found that that prescribing 
rates of antidepressants and gabapentinoids among the 
adult English population in primary care increased in 
recent years to 15.8% and 3.3%, respectively: conversely, 
opioid analgesics, benzodiazepines and z- drugs (such 
as zopiclone) slightly reduced, though still prevalent 
with 13%, 3% and 2%, respectively, of the total popu-
lation currently being prescribed these medicines.40 
Consequently, the National Institute for Health and Care 
Excellence is developing guidelines for the management 
of medicines associated with dependence or withdrawal 
symptoms.41 However, not all medicines that are used 
inappropriately are necessarily associated with addic-
tion, dependency or withdrawal symptoms, and the 
PHE review40 did not consider all types of medication or 
different treatment settings such as specialist SMS.
The UK’s Clinical Guidelines on Drug Misuse and 
Dependence42 outline that there is a limited evidence base 
available to inform the clinical management of individuals 
who require support. This is especially important where 
illicit substances are used alongside OTC and/or POMs 
because this may be associated with a lower quality of life 
and greater mental health issues.43 It is, therefore, essen-
tial to be able to offer timely and effective interventions 
to reduce the risk of using other substances, experiencing 
more severe functional problems and riskier drug- related 
behaviours.44 Additionally, substitute treatment used in 
SMS may also be used inappropriately and people who 
access SMS are more likely to experience comorbid 
mental health conditions, be prescribed psychotropic 
medication and for unlicensed indications.45 46
Data from the USA suggest that once people who 
need support with their problematic OTC and/or POM 
use are engaged in treatment, then retention and absti-
nence rates are thought to be favourable, so identi-
fying their demographic characteristics may assist with 
improving associated SMS outcomes.47 48 The charac-
teristics of people who use OTC and/or POMs may be 
different in other countries such as the UK and may be 
different to those who choose to primarily use ‘street’ 
drugs; however, people who use ‘street’ drugs or who 
may be in receipt of substitute treatments from SMS are 
also known to misuse OTC and POMs.49 50 For example, 
in the UK, 69% of people seeking support from SMS 
are men51; however, the 2019 PHE review and the asso-
ciated publication by Marsden et al52 identified higher 
rates of prescribing for women of medication associated 
with dependency and withdrawal.40 Other studies have 
found that women may have a greater propensity for 
some types of OTC and POM misuse or be more likely 
to experience more severe outcomes and subsequently 
account for an increasing proportion of associated 
emergency department admissions.53–55 Furthermore, 
older age, residing in areas of greater deprivation, 
comorbid chronic pain issues and HIV- positive status 
may also increase risk of misuse, but this may vary by 
the type of medication.40 47 53–59 Such medicines may be 
legally sourced via prescriptions and pharmacy sales and 
sometimes multiple outlets or healthcare professionals 
are visited to obtain supplies; however, they may also be 
obtained illegally, for example, from street dealers or 
unregulated internet purchases.49
There are currently no other known systematic reviews 
that have focused on the misuse of OTC or POM by people 
accessing SMS. This protocol is for such a systematic review 
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for Systematic Reviews and Meta- Analyses (PRISMA),60 
and using the PRISMA- Protocols (PRISMA- P) checklist.61
Aim and objectives
This protocol outlines how a systematic review will be 
undertaken, which aims to examine the literature on the 
pattern of OTC and POM misuse among adults who are 
accessing substance misuse treatment services. The objec-
tives of the systematic review are to identify the types of 




This review will consist of published studies that must 
meet all the following criteria:
 ► Adult participants (18 years or over).
 ► Individuals receiving interventions for substance 
misuse in any setting (eg, prison, community, 
hospital).
 ► People who are inappropriately using (misusing) 
OTC and/or POM for nonmedical purposes.
 ► Individuals in receipt of psychological and/or phar-
macological interventions for their substance use.
Prescription medication will not include those that are 
being prescribed to the individual for the management 
of their substance misuse disorder. There will be no other 
restrictions on the type of study population or publication 
time period. Letters and comments outlining the views, 
experiences and opinions of individual professionals, 
researchers, commentators or patients will be excluded; 
however, reports that summarise and/or collate indi-
vidual experiences will be considered. For practical 
reasons, results from all countries and in all languages 
will be noted; however, only English language results will 
be considered.
Information sources
Library staff from Aston University verified the suitability 
of the search strategy. The reference lists of eligible studies 
will be manually searched to identify any additional rele-
vant citations to ensure a comprehensive search.
Search
A comprehensive search of the published literature will 
be undertaken during June 2021 using the Cochrane,62 
OVID Medline,63 Pubmed,64 Scopus65 and Web of Science 
Core Collection66 databases. Grey literature will also be 
checked for relevant information. A combination of 
keywords, medical subject heading and Boolean oper-
ator terms related to prescription, and OTC medication 
misuse in substance misuse treatment will be used such as 
(Over- the- Counter Drug Misuse) OR (Prescription Drug 
Misuse) AND (Substance Abuse Treatment Centers). See 
online supplemental file 1.
Study selection
Two independent reviewers (RG and LM) will conduct the 
initial title and abstract screenings, followed by full- text 
reviews, using predetermined criteria for inclusion and 
exclusion. A third reviewer (IM) will resolve disagree-
ments if consensus cannot be reached.
Data collection process
If selected for inclusion, full- text data extraction will be 
conducted using a pilot- tested data extraction form. An 
iterative approach will be taken to improve the usability 
and to assure the functionality of the forms during the 
piloting process. Completed pilot forms will be assessed 
to ensure that they are fit for purpose and that a consis-
tent approach is taken by both reviewers. Where possible, 
the authors of the papers will be contacted to provide any 
missing information. The extracted data will be simulta-
neously captured by both reviewers using Google forms, 
which all reviewers are familiar with. Patients were not 
directly involved in the protocol design study and partic-
ipant recruitment is not required for a systematic review, 
so disseminating findings to participants is not applicable.
Data items
The form prompts for retrieval of data including primary 
author surname, year of publication, title of the publica-
tion and journal name, details of medication and other 
substances, sample size and characteristics, study design, 
setting, methodology, statistical methods and results, 
summary of findings and limitations.
Risk of bias
Quality scores from the Mixed Methods Appraisal Tool 
(MMAT)67 will be used to assess the risk of bias as this 
tool accommodates quantitative, qualitative and mixed 
methods, so the same tool can be used for all studies. If 
appropriate, for systematic reviews, the MMAT will be 
supplemented by A Measurement Tool to Assess System-
atic Reviews version 2.68 They will be applied by the 
reviewers (RG and LM) independently, and the results 
will be tabulated to enable easy comparison. Similarly, as 
with data extraction methodology, discrepancies will be 
discussed and a third reviewer (IM) will be consulted to 
resolve any disagreements.
Summary measures
OTC and POM misuse by adults who are receiving treat-
ment for substance misuse may be determined in a multi-
tude of ways. The identification of the types of medication 
being taken, prevalence and associated demographic 
characteristics will be considered.
Patient and public involvement
No patient involved.
Synthesis of results
All included studies will be appraised with a qualitative 
summary. The synthesis of qualitative data will follow a 
thematic analysis approach and the main review findings 
will be summarised in table format using MS Excel. If the 
quantitative data allow, a meta- analysis will be undertaken 
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numerical descriptors will be captured as a narrative. Quan-
titative data synthesis methodology and potential for meta- 
analysis will be dependent on the number and quality of 
studies identified. Heterogeneity will be assessed using the 
I² test, and as outlined by Higgins and Green,69 heteroge-
neity is impacted by a variety of factors, so cut- off values will 
not be enforced; however, heterogeneity will be considered 
likely if I² is greater than 40%. If this occurs, subgroup anal-
yses will be undertaken and it may be more likely to occur, 
for example, for age, gender and type of medication.
As proposed by Campbell et al70, if a meta- analysis is not 
possible, then Synthesis Without Meta- analysis (SWiM) 
will be undertaken due to the shortcomings associated 
with narrative synthesis, and in order to complement 
PRISMA. Similar to the data extraction process, an inde-
pendent second review reviewer (LM) will quality assure 
the analysis, and discrepancies between reviewers will be 
identified and resolved through discussion (with a third 
reviewer (IM) where necessary). The resulting cumulative 
strength of the quality of evidence will be assessed using 
Grading of Recommendations, Assessment, Development 
and Evaluation.71
Ethics and dissemination
Ethical approval is not required for a secondary data anal-
ysis. The findings will be published in a peer- reviewed 
journal and at conferences, shared verbally, electronically 
and in print, with interested clinicians and policymakers.
DISCUSSION
As all reviewers will be using the same data collection 
form, which is piloted for suitability of use, this will enable 
the data extraction process to be standardised. Having 
two reviewers independently undertaking study selection, 
data extraction and assessment of risk bias and a third 
reviewer to resolve disagreements and review findings as 
well as the use of the MMAT67 will strengthen the quality 
assurance process.
Internationally validated tools will be used for data 
syntheses where available. For example, the findings will 
be reported in line with PRISMA,60 and a flow diagram 
will be used to capture the study selection (and exclusion) 
process. A lack of high- quality studies may be a limitation, 
and their diversity may further limit the potential for 
meta- analyses for quantitative data. If this is the case, then 
SWiM70 will be used to add robustness.
Undertaking this systematic review will enable a greater 
understanding of the current published evidence base 
relating to the pattern of OTC and POM misuse by adults 
who are accessing SMS. The resulting critique of the find-
ings is important given the increasing concerns about this 
issue and will be useful to identify areas on which to focus 
future research.
Twitter Rosalind Gittins @Roz_Gittins and Ian Maidment @maidment_dr
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